Recombinant human sickle hemoglobin expressed in yeast

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Sickle cell disease is caused by a mutation in the beta-globin gene, leading to abnormal hemoglobin S (HbS).
• Studying HbS aggregation is key to understanding disease pathology and developing therapies.
• Previous expression systems had limitations in accurately replicating human hemoglobin processing.

Purpose of the Study:

• To express functional sickle hemoglobin (HbS) in the yeast Saccharomyces cerevisiae.
• To compare yeast expression with bacterial systems for recombinant DNA studies of HbS.
• To establish a system for studying HbS aggregation and exploring therapeutic interventions.

Main Methods:

• Site-directed mutagenesis and cassette mutagenesis were used to introduce the sickle mutation into human globin genes on a plasmid.
• Recombinant HbS was expressed in yeast (Saccharomyces cerevisiae).
• Purification of recombinant HbS was achieved using a single-column procedure.

Main Results:

• Recombinant HbS produced in yeast was biochemically and functionally identical to natural sickle hemoglobin.
• Yeast expression systems correctly process N-terminal valine residues, unlike bacterial systems.
• The yeast system facilitates the study of HbS aggregation and potential therapeutic targets.

Conclusions:

• Yeast is a suitable and preferable expression system for producing recombinant sickle hemoglobin for research.
• This engineered system enables detailed investigation into the role of specific amino acid side chains in HbS aggregation.
• The findings pave the way for developing novel therapeutic strategies for sickle cell disease.